Symptoms and treatment in cancer therapy-induced early menopause

被引:44
作者
Boekhout, Annelies H.
Beijnen, Jos H.
Schellens, Jan H. M.
机构
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands
[2] Univ Utrecht, Fac Pharmaceut Sci, Div Biomed Anal, Utrecht, Netherlands
关键词
hotflashes; pathophysiology; epidemiology; complementary therapies; clonidine; gabapentin; selective serotonin reuptake inhibitors; breast neoplasm;
D O I
10.1634/theoncologist.11-6-641
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Young women with breast cancer often experience early menopause as a result of the therapy for their malignant disease. The sudden occurrence of menopause resulting from chemotherapy, oophorectomy, radiation, or gonadal dysgenesis frequently results in hot flashes that begin at a younger age and may occur at a greater frequency and intensity than hot flashes associated with natural menopause. Hormone therapy relieves symptoms effectively in 80%-90% of women who initiate treatment. This therapy, however, is generally contraindicated in estrogen-dependent cancers, such as breast cancer, because of the potentially increased risk for recurrence. Many agents have been investigated as potential means for alleviating hot flashes in survivors of breast cancer, such as progestagens, clonidine, gabapentin, and antidepressants. Several complementary and alternative medicines frequently used by patients have also been studied. These include black cohosh, phytoestrogens, homeopathy, vitamin E, acupuncture, and behavior strategies. To support the use of one of more of these nonpharmacological or pharmacological options in the treatment of hot flashes in breast cancer patients, more evidence from well-controlled clinical trials is needed. In particular, soundly based scientific research with complementary and alternative medicine therapies is lacking. Pharmacological treatments appear to be more beneficial than nonpharmacological treatments. This article reviews the current literature to assess the epidemiology and diagnosis of hot flashes and the nonpharmacological and pharmacological options for the treatment of hot flashes, in breast cancer patients in particular. When specific treatment options have not been evaluated in breast cancer patients specifically, published data on the management of hot flashes with this modality in healthy postmenopausal women are described.
引用
收藏
页码:641 / 654
页数:14
相关论文
共 96 条
[1]   The effect of dietary soy supplementation on hot flushes [J].
Albertazzi, P ;
Pansini, F ;
Bonaccorsi, G ;
Zanotti, L ;
Forini, E ;
De Aloysio, D .
OBSTETRICS AND GYNECOLOGY, 1998, 91 (01) :6-11
[2]   Red clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165] [J].
Atkinson, C ;
Warren, RML ;
Sala, E ;
Dowsett, M ;
Dunning, AM ;
Healey, CS ;
Runswick, S ;
Day, NE ;
Bingham, SA .
BREAST CANCER RESEARCH, 2004, 6 (03) :R170-R179
[3]  
Barton Debra, 2002, Oncol Nurs Forum, V29, P33, DOI 10.1188/02.ONF.33-40
[4]   Prospective evaluation of vitamin E for hot flashes in breast cancer survivors [J].
Barton, DL ;
Loprinzi, CL ;
Quella, SK ;
Sloan, JA ;
Veeder, MH ;
Egner, JR ;
Fidler, P ;
Stella, PJ ;
Swan, DK ;
Vaught, NL ;
Novotny, P .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :495-500
[5]   Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study [J].
Bertelli, G ;
Venturini, M ;
Del Mastro, L ;
Bergaglio, M ;
Sismondi, P ;
Biglia, N ;
Venturini, S ;
Porcile, G ;
Pronzato, P ;
Costantini, M ;
Rosso, R .
ANNALS OF ONCOLOGY, 2002, 13 (06) :883-888
[6]   OVARIAN ABLATION VERSUS GOSERELIN WITH OR WITHOUT TAMOXIFEN IN PRE-PERIMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER - RESULTS OF A MULTICENTRIC ITALIAN STUDY [J].
BOCCARDO, F ;
RUBAGOTTI, A ;
PERROTTA, A ;
AMOROSO, D ;
BALESTRERO, M ;
DEMATTEIS, A ;
ZOLA, P ;
SISMONDI, P ;
FRANCINI, G ;
PETRIOLI, R ;
SASSI, M ;
PACINI, P ;
GALLIGIONI, E .
ANNALS OF ONCOLOGY, 1994, 5 (04) :337-342
[7]   Influence of marketed herbal menopause preparations on MCF-7 cell proliferation [J].
Bodinet, C ;
Freudenstein, J .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2004, 11 (03) :281-289
[8]   Cimicifuga racemosa:: a systematic review of its clinical efficacy [J].
Borrelli, F ;
Ernst, E .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (04) :235-241
[9]  
BULLOCK JL, 1975, OBSTET GYNECOL, V46, P165
[10]  
Carpenter JS, 1998, CANCER-AM CANCER SOC, V82, P1682, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1682::AID-CNCR14>3.3.CO